Iovance set the price based on Amtagvi’s value as the first drug approved in this post-PD-1 melanoma setting, as well as the company’s analysis of relevant benchmarks, Vogt said. Similar to ...

For a full overview of Iovance's long and somewhat tortuous journey to becoming potentially the first company to secure a Food and Drug Agency ("FDA") approval for a cell therapy targeting solid ...

An Iovance Biotherapeutics treatment employing a different type of cell has won accelerated FDA approval for advanced melanoma, marking the first product approval of any cell therapy for a solid ...

but they reiterated a Buy rating due in part to the potential of Iovance’s melanoma drug Amtagvi. Iovance expects regulatory approval for Amtagvi in the European Union, United Kingdom, and Canada this ...

Iovance is also conducting TILVANCE-301, a Phase 3 trial to confirm clinical benefit. AMTAGVI is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid ...

“The first quarter of 2024 was transformative for Iovance following our first FDA approval and our strong start for the U.S. commercial launch of Amtagvi™ for patients with advanced melanom ...

Iovance has its gene therapy manufacturing plant at the Philadelphia Navy Yard. Iovance officially opens $125M cell therapy center at the Navy Yard © 2025 American ...

Iovance’s main growth engine is Amtagvi, which is the first FDA-approved TIL cell therapy for advanced melanoma post-anti-PD-1 treatment. In 2024, Amtagvi generated $103.6 million in revenue and ...

The company has relied on issuing stock to fund its operations over the years -- and that's a pattern that may continue for the foreseeable future. As long as Iovance's cash burn remains high, ...

This clinical hold came after a patient in the study died. Iovance awaits an FDA approval decision on lead candidate lifileucel in treating advanced melanoma. The FDA's clinical hold was put into ...

Though the condition is uncommon, cancer experts say winning FDA approval could mark the beginning of a potent new weapon against far more common tumors. Shares of Iovance Biotherapeutics ...

This grant is a part of Iovance's strategy to innovate and develop tumor infiltrating lymphocyte therapies for cancer patients, building on their success with FDA-approved products like Amtagvi®.